ALLURION TECHNOLOGIES INC Stock Price, News & Analysis

Allurion Technologies (NYSE: ALUR), a company focused on metabolically healthy weight loss, announced that its Founder and CEO, Dr. Shantanu Gaur, will deliver a presentation at the Jefferies Global Healthcare Conference in New York. The presentation is scheduled for June 4 at 3:45 p.m. ET. Interested parties can access the webcast through the Events & Presentations section of Allurion's investor relations website.

Allurion Technologies (NYSE: ALUR) presented significant clinical results at the SOFFCO.MM meeting in France, showcasing the effectiveness of their Allurion Program for weight loss. The study of 1,962 French patients demonstrated remarkable outcomes after four months:

- 12.2% average reduction in total body weight
- 6.6% increase in muscle mass percentage
- 11% decrease in fat mass
- 12.2% reduction in visceral fat index

Additionally, the company announced the resumption of shipments to France, with patient treatments expected to restart next month, marking their return to the French market with a focus on metabolically healthy weight loss.

- Patients using GLP-1s with the Virtual Care Suite showed a 6.1% increase in lean body mass and 6.4% increase in muscle mass

- Combination therapy of Allurion Balloon with semaglutide achieved 21.2% body weight reduction, comparable to bariatric surgery outcomes

- The Allurion Program without GLP-1s demonstrated 12.4% weight reduction and 9.8% muscle mass increase in 2,000 patients

The studies suggest that Allurion's AI-driven behavioral support may help maintain muscle mass during GLP-1 therapy, while combination treatments could offer alternatives to bariatric surgery for severe obesity cases.

Allurion Technologies (NYSE: ALUR), a company focused on obesity treatment, has scheduled its first quarter 2025 financial results announcement for May 14, 2025. The company will host a conference call and webcast at 8:30 AM ET on the same day to discuss the results and provide a business update.

Participants can join via phone by dialing (888) 330-3417 (domestic) or +1 646 960 0804 (international) using Conference ID 1905455. The webcast will be available in the Events section of Allurion's Investor Relations website. A replay will be accessible by phone at (800) 770-2030 using Access Code 1905455, and the archived webcast will remain available on the company's website.

Allurion Technologies (NYSE: ALUR) has announced the postponement of its Special Meeting of Stockholders from April 4, 2025, to Thursday, April 10, 2025, at 12:00 p.m. (Eastern Time). The virtual meeting will be held via live audio webcast.

The postponement aims to allow additional time for proxy solicitation and provide stockholders more time to vote. The record date remains unchanged at March 14, 2025. Previously cast votes will remain valid unless stockholders choose to change or revoke them.

The Company's Board of Directors unanimously recommends voting FOR the proposals outlined in the Definitive Proxy Statement filed on March 24, 2025. Stockholders can access detailed information and voting instructions through the SEC website or Allurion's investor relations page.

Allurion Technologies (NYSE: ALUR) reported its Q4 and full-year 2024 financial results. Q4 revenue was $5.6 million with full-year revenue reaching $32.1 million. The company faced challenges with Q4 gross profit at $2.5 million (45% margin), down from $6.4 million (78% margin) in Q4 2023.

Key developments include:

• Resumed sales in France on February 12, 2025
• Positive topline results from AUDACITY FDA trial
• Initial data showing promising results combining Allurion Program with low-dose GLP-1s
• Launch of next-generation Allurion Balloon with smaller capsule size

The company reduced Q4 2024 operating expenses by 39% year-over-year to $19.6 million, including $3.8 million in restructuring charges. For 2025, Allurion projects revenue of approximately $30 million and plans to cut operating expenses by roughly 50% compared to 2024.

Allurion Technologies (NYSE: ALUR) has revealed promising initial results from combining the Allurion Program with low-dose GLP-1 therapy. The study involved 52 patients who received the Allurion Balloon and started on 0.25mg semaglutide, gradually increased to 1.0mg over 6 months.

Key findings after 8 months include:

• 20.3% average total body weight loss
• 15% increase in lean body mass (from 59.6% to 68.5%)
• 100% patient adherence to GLP-1 medication

This combination approach addresses common challenges with standalone GLP-1 therapy, which typically shows 40% reduction in lean mass and high discontinuation rates (30% in first month, 58% before reaching meaningful health benefits). The study used lower semaglutide doses (max 1.0mg) compared to typical 2.4mg dosing, resulting in fewer side effects and better adherence.

Allurion Technologies (NYSE: ALUR), an anti-obesity focused company, has scheduled its fourth quarter 2024 financial results announcement for March 26, 2025. The company will host a conference call and webcast at 8:30 AM ET on the same day to discuss the results and provide a business update.

Investors can access the conference call via phone at (888) 330-3417 (domestic) or +1 646 960 0804 (international) using Conference ID 1905455. A live audio webcast will be available in the Events section of Allurion's Investor Relations website. A replay will be accessible by phone using Access Code 1905455 and through the archived webcast on the company's IR website.